Bipolar 2 Depression

The short version

●Bipolar 2 disorder is defined by one or more major depressive episodes plus at least one hypomanic episode (≥4 days of elevated, expansive, or irritable mood with associated symptoms), and no full manic episode.
●The depressive phase dominates the clinical course — patients spend approximately 35-50x more time depressed than hypomanic in published longitudinal cohorts. The depression is what brings most patients into care.
●Treatment differs substantially from unipolar depression. Antidepressant monotherapy is generally avoided because of mania-induction risk and switch into rapid cycling. Mood stabilizers are foundational.
●First-line treatments for bipolar 2 depression: lithium, lamotrigine, quetiapine, and lurasidone have the strongest evidence base. Antidepressants are used cautiously and only with a concurrent mood stabilizer.
●Ketamine in bipolar 2 has emerging evidence (Wilkowska, Diazgranados, and others). The key clinical consideration: ketamine has antidepressant effect in bipolar depression, but mood elevation risk is real and concurrent mood stabilizer is essentially mandatory.
●Underdiagnosis is common: bipolar 2 patients often present in depressive phase and do not spontaneously report hypomania (which they may not recognize as pathological). Screening with MDQ or structured interview should be standard in apparent treatment-resistant unipolar depression.

Clinical definition

DSM-5-TR bipolar 2 disorder requires: at least one major depressive episode (5+ symptoms over 2+ weeks with depressed mood or anhedonia), at least one hypomanic episode (4+ days of elevated, expansive, or irritable mood plus 3+ of: inflated self-esteem, decreased sleep need, more talkative, racing thoughts, distractibility, increased activity, excessive pleasurable but risky activity), and no full manic episode (which would be bipolar 1). Hypomania is distinguished from mania by duration (4+ days vs 7+) and severity (no marked impairment, no hospitalization, no psychotic features). The depressive phase typically dominates the clinical course — Judd and colleagues' longitudinal data found patients spent approximately 50% of follow-up time depressed and only 1-2% hypomanic. Cycling patterns vary: some patients have clear episode boundaries; others have rapid cycling (4+ episodes per year) or mixed features. Lifetime prevalence approximately 0.5-1% in U.S. samples but likely underestimated because of missed hypomanic episodes. Berk 2025 World Psychiatry provides a current state-of-the-art review.

How it differs from related conditions

vs. Bipolar 1 disorder

Bipolar 1 requires at least one full manic episode (≥7 days, marked impairment, hospitalization possible). Bipolar 2 requires hypomania (≥4 days, no marked impairment) and at least one major depressive episode. The severity threshold of the highest mood elevation defines the distinction.

vs. Major depressive disorder (unipolar)

MDD has only depressive episodes; bipolar 2 has both depressive episodes AND at least one hypomanic episode. Misdiagnosis is common — patients with bipolar 2 often present in depressive phase and do not report hypomania spontaneously. Screening (MDQ) and structured history-taking matter.

vs. Cyclothymic disorder

Cyclothymia involves sub-syndromal hypomanic and depressive symptoms for ≥2 years without ever meeting full episode criteria. Bipolar 2 requires at least one full hypomanic episode plus at least one full major depressive episode. Cyclothymia can progress to bipolar 2.

vs. Borderline personality disorder (BPD)

BPD mood lability is typically minute-to-hours, triggered by interpersonal events, and accompanied by characteristic interpersonal patterns. Bipolar 2 hypomania is sustained 4+ days, not directly triggered, and reflects categorical mood elevation. Substantial overlap and frequent co-occurrence; distinguishing matters because treatment differs.

First-line treatments

Lithium

Long-established first-line mood stabilizer with antimanic and antidepressant effects, plus the most robust evidence for suicide prevention in bipolar disorder. Target serum level 0.6-1.0 mEq/L for maintenance. Requires monitoring (thyroid, renal, lithium levels). Narrow therapeutic window; toxicity considerations. Effective for both phases of bipolar 2.

Lamotrigine

First-line for bipolar 2 depression specifically. Particularly useful in patients whose course is dominated by depression rather than hypomania. Slow titration required (over 6-8 weeks) to minimize Stevens-Johnson syndrome risk. Generally well-tolerated at target dose 200mg/day; minimal metabolic side effects compared to atypical antipsychotics.

Quetiapine (Seroquel)

FDA-approved for acute bipolar depression. Effective for both bipolar 1 and bipolar 2 depressive episodes. Dose for depression typically 300mg/day; sedation often prominent (administer at bedtime). Metabolic side effects (weight, lipids, glucose) require monitoring. Useful for patients with prominent insomnia alongside depression.

Lurasidone (Latuda)

FDA-approved for bipolar depression in monotherapy and adjunctive use with lithium or valproate. Effect sizes in bipolar 2 specifically less robust than for bipolar 1 but reasonable. Lower metabolic burden than quetiapine. Must be taken with food (≥350 calories) for adequate absorption.

Antidepressants WITH mood stabilizer (cautious)

SSRIs or bupropion added to lithium, lamotrigine, or quetiapine may help residual depressive symptoms. Antidepressant MONOTHERAPY in bipolar 2 is generally avoided because of mania-induction and rapid-cycling risk. SNRIs and tricyclics carry higher switch risk than SSRIs or bupropion. Continue antidepressant only as long as benefit clearly outweighs risk.

CBT and psychoeducation

Bipolar-specific psychotherapy (Frank and colleagues' Interpersonal and Social Rhythm Therapy; Miklowitz family-focused therapy) reduces relapse rates when added to pharmacotherapy. Psychoeducation about prodromal hypomanic signs is itself protective — patients who recognize early elevation can seek treatment adjustment before full episode.

Sleep regularization

Sleep loss is a documented trigger for hypomanic switch in bipolar 2. Maintaining consistent sleep schedule, avoiding all-nighters, and structured sleep hygiene are non-negotiable elements of bipolar 2 management. Particularly important during depressive phase when patients may oversleep, potentially triggering switch on recovery.

When standard treatments fail

For treatment-resistant bipolar 2 depression: optimize current mood stabilizer (consider switching to or adding lithium if not already on it) → consider adjunctive atypical antipsychotic (quetiapine or lurasidone if not used) → consider ketamine WITH concurrent mood stabilizer → consider ECT (highly effective in severe bipolar depression) → consider pramipexole (limited but suggestive evidence). The clinical sequence in bipolar 2 differs from unipolar TRD primarily in the mandatory presence of a mood stabilizer at every step. Antidepressant trials in isolation should not be considered "failures" in the bipolar 2 context — they may have failed because they were inappropriate without mood stabilization. Reassessment of the bipolar diagnosis matters when expected treatments fail unusually; some apparent bipolar 2 patients have ultra-rapid cycling unipolar depression or BPD that mimics bipolar features.

Where ketamine fits

Ketamine in bipolar 2 depression has accumulating evidence (Diazgranados 2010, Zarate 2012, and Wilkowska 2023 review). The antidepressant effect appears similar to unipolar depression — rapid onset, transient duration of single-session benefit. The CRITICAL clinical consideration: ketamine can plausibly induce hypomania or mania, particularly in patients not on adequate mood stabilization. Published case reports of ketamine-induced mood elevation exist. Honest clinical framing: ketamine in bipolar 2 is an option, not a contraindication, but it must be done with concurrent mood stabilizer (lithium, lamotrigine, quetiapine, or lurasidone at therapeutic dose) and with prepared monitoring for mood elevation. Patients are instructed to report sleep changes, energy elevation, or grandiose thinking immediately, and clinicians should have plans for rapid de-escalation. The risk-benefit calculation differs from unipolar TRD; informed consent must explicitly address mania-induction risk.

Where this fits with Tovani

Tovani treats bipolar 2 depression only when the patient is on a stable, therapeutic dose of mood stabilizer (lithium, lamotrigine, quetiapine, or lurasidone) and under concurrent psychiatric care. The eligibility screening explicitly checks for bipolar 2 (via MDQ and structured questions). Patients with apparent unipolar TRD who screen positive for bipolar 2 are not denied treatment but are required to first establish stable mood-stabilizer therapy with a psychiatrist before ketamine can begin. The physician check-in pays particular attention to sleep quality, energy levels, and prodromal hypomanic signs throughout treatment. Patients are explicitly briefed on what to watch for and how to contact the clinic if mood elevation emerges.

Check eligibility The science behind ketamine

Frequently asked

How do I know if my depression is unipolar or bipolar 2?

A psychiatric evaluation with structured screening (Mood Disorder Questionnaire / MDQ) and detailed history of past mood elevation episodes is the answer. Patients with bipolar 2 often do not spontaneously report hypomania — they may have experienced past periods of unusually high energy, decreased sleep need, increased productivity, or racing thoughts that they did not recognize as pathological. A clinician asks specifically about these.

Can I take antidepressants for bipolar 2 depression?

With caution and only alongside a mood stabilizer. Antidepressant monotherapy in bipolar 2 is generally avoided because of mania-induction and rapid-cycling risk. SSRIs or bupropion added to lithium, lamotrigine, quetiapine, or lurasidone may help residual depressive symptoms when needed. Tricyclics and SNRIs carry higher switch risk and are typically avoided when possible.

Is ketamine safe for bipolar 2?

It can be used safely with concurrent mood stabilization and careful monitoring. The clinical considerations: ketamine can induce mood elevation in bipolar 2 patients (case reports exist); concurrent mood stabilizer at therapeutic dose is essentially mandatory; monitoring for sleep changes, energy elevation, and grandiose thinking is part of treatment; patients need explicit briefing on warning signs. With these protections, ketamine is a reasonable option for bipolar 2 depression unresponsive to standard treatment.

What if ketamine triggers a hypomanic episode?

Mood elevation during ketamine treatment is managed by: pause additional sessions, ensure mood stabilizer is at therapeutic dose (raise if needed), add or increase atypical antipsychotic (quetiapine, olanzapine, lurasidone) acutely, address sleep loss aggressively, and reassess whether ketamine treatment should continue. Most cases of ketamine-induced mood elevation respond to dose adjustment and time; resuming treatment with greater protection (higher mood stabilizer dose, lower ketamine dose, more space between sessions) is often possible.

Will I always need a mood stabilizer?

Generally yes — bipolar 2 is a lifelong condition with high recurrence risk. Discontinuing a mood stabilizer that has produced stable response is typically unwise because relapse rates are high. The conversation may shift over time about specific medications and doses, but most patients with bipolar 2 benefit from ongoing mood-stabilizer therapy for years to indefinitely.

References

Berk M et al. 2025, World Psychiatry — State-of-the-art review of bipolar 2 disorder — current diagnostic criteria, clinical course, treatment evidence base for the depressive phase, and considerations for sequencing pharmacotherapy in bipolar 2 specifically. (PMID 40371769)
Sanacora G et al. 2017, JAMA Psychiatry — APA consensus statement on ketamine in mood disorders — addresses use in bipolar depression including mania-induction risk and the requirement for concurrent mood stabilization. (PMID 28249076)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression — foundational evidence for ketamine's rapid antidepressant mechanism, with subsequent extension to bipolar depression populations. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.